<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107639</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 75/08</org_study_id>
    <secondary_id>2009-016584-10</secondary_id>
    <secondary_id>EU-21024</secondary_id>
    <secondary_id>CDR0000669249</secondary_id>
    <nct_id>NCT01107639</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in
      chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of
      tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
      antibodies, such as cetuximab, can block tumor growth in different ways. Some block the
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
      carry tumor-killing substances to them. It is not yet known whether giving radiation therapy
      together with chemotherapy is more effective with or without cetuximab in treating patients
      with esophageal cancer.

      PURPOSE: This randomized phase III trial is studying giving radiation therapy together with
      chemotherapy, with or without cetuximab, followed by surgery in treating patients with
      locally advanced esophageal cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the efficacy of neoadjuvant radiochemotherapy comprising docetaxel,
           cisplatin, and radiotherapy in combination with cetuximab followed by surgery and
           adjuvant cetuximab versus neoadjuvant radiochemotherapy comprising docetaxel, cisplatin,
           and radiotherapy followed by surgery in patients with locally advanced esophageal
           carcinoma.

      Secondary

        -  To compare the toxicity of the two therapy arms.

        -  To determine patterns of failure overall and with regard to histology.

        -  To evaluate economic aspects in a subproject and to perform a radiotherapy quality
           assurance program.

      OUTLINE: This is a multicenter study. Patients are stratified according to center, histology
      (adenocarcinoma vs squamous cell carcinoma), primary tumor (T2 vs T3-4), and gender (male vs
      female). Patients are randomized to 1 of 2 treatment arms.

        -  Arm A:

             -  Induction chemotherapy (docetaxel and cisplatin) and concurrent cetuximab Patients
                receive docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1 and
                cetuximab IV over 1-2 hours on day 1, 8, and 15. Treatment repeats every 21 days
                for 2 courses.

             -  Chemotherapy (docetaxel and cisplatin), cetuximab, and concurrent radiotherapy
                Beginning in week 7, patients receive cetuximab IV over 1 hour, docetaxel IV over
                30 minutes, cisplatin IV over 1 hour on days 43, 50, 57, 64, and 71 and undergo
                radiotherapy 5 days a week for 5 weeks. Patients then undergo surgery 4-7 weeks
                after completion of radiotherapy.

             -  Adjuvant cetuximab Beginning 3-6 weeks after completion of surgery, patients
                receive cetuximab IV over 1-2 hours once every 2 weeks for a total of 6 doses.

        -  Arm B: Patients receive induction chemotherapy comprising docetaxel IV and cisplatin IV
           for 2 courses as in arm A. Beginning in week 7, patients receive docetaxel IV, cisplatin
           IV, and concurrent radiotherapy for 5 weeks as in arm A. Patients then undergo surgery
           4-7 weeks after completion of radiotherapy.

      After completion of study therapy, patients are followed up at 1 (arm B) or 6 (arm A) months,
      every 3 months for 3 years, and then every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2010</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">October 6, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>time from randomization to a defined event.</time_frame>
    <description>time from randomization to one of the following events, whichever comes first:
Tumor progression at any time (progression of primary tumor or local lymph nodes, appearance of new lesions)
Recurrence at local, regional or distant site after surgery
Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival after surgery</measure>
    <time_frame>from date of surgery to an event as defined in PFS.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to CTCAE version 4.0 and major postoperative complications</measure>
    <time_frame>during treatment and follow-up period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological remission</measure>
    <time_frame>Assessed according to the tumor regression model of Mandard</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time from trial randomization to the date of death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to locoregional failure after R0 resection</measure>
    <time_frame>from date of surgery to date of first documented loco-regional failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to systemic failure after R0 resection</measure>
    <time_frame>from date of surgery to date of first documented systemic failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>occurring after surgery but while the patient remains in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Time to progression is defined as time from randomization to one of the following events, whichever comes first: - Tumor progression at any time. - Recurrence at local, regional or distant site after surgery. - Death due to tumor</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">297</enrollment>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without additional immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard therapy without immunotherapy (cetuximab).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion</description>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m2 1h infusion d1, 22
Cisplatin 25 mg/m2 1h infusion weekly x5</description>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
    <arm_group_label>Without additional immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 1h infusion d1, 22
Docetaxel 20 mg/m2 1/2h infusion weekly x5</description>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
    <arm_group_label>Without additional immunotherapy</arm_group_label>
    <other_name>Taxotere or generic product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².</description>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.</description>
    <arm_group_label>Additional immunotherapy (cetuximab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed esophageal carcinoma

          -  Meets the following criteria:

               -  Resectable, locally advanced disease as determined by the combination of CT scan,
                  endoluminal ultrasound (EUS), PET scan, and a multidisciplinary team discussion

                    -  T2, N1-3; T3, any N; or T4a, any N (if technically resectable with curative
                       intent [R0] as decided by a multidisciplinary team discussion)

                         -  EUS-guided fine-needle aspiration (FNA) allowed, but determines nodal
                            status only if positive FNA

                    -  No T1, any N, M0; or T2, N0, M0; T4a (due to infiltration of the
                       trachea-bronchial tree or organ involvement that cannot be operated on with
                       curative intent [R0] as decided by a multidisciplinary team discussion);
                       T4b; or distant metastasis (M1)

               -  Type I or II disease according to the Siewert classification

               -  Squamous cell carcinoma (including basaloid-squamous cell and adenosquamous
                  carcinoma) or adenocarcinoma of the thoracic esophagus or the esophagogastric
                  junction (from 5 cm below the entrance of the esophagus into the thorax to the
                  gastric cardia)

          -  Patients with obstructive tumors are eligible (obstructive tumors will be considered
             as locally advanced tumors)

          -  No cervical esophageal carcinoma and tumors involving the first 5 cm of the thoracic
             esophagus

          -  No airway infiltration in case of tumors at or above the tracheal bifurcation

          -  No peritoneal carcinomatosis in case of adenocarcinomas infiltrating the gastric
             cardia (i.e., esophagogastric junction carcinoma Siewert type I or II)

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  Neutrophil count ≥ 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Creatinine clearance &gt; 60 mL/min

          -  Bilirubin ≤ 1.0 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  AST ≤ 1.5 times ULN

          -  INR normal

          -  PTT ≤ 1.0 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 12 months after
             completion of study therapy

          -  FEV_1 ≥ 1.5 L OR ≥ 75% of the reference value

          -  Must be compliant and geographically proximal for staging and follow-up

          -  Considered operable (i.e., appropriate organ functions and ability to undergo general
             anesthesia)

          -  No other malignancies within the past 5 years except nonmelanomatous skin cancer or
             adequately treated carcinoma in situ of the cervix

          -  No severe or uncontrolled cardiovascular disease, including any of the following:

               -  NYHA class III-IV congestive heart failure

               -  Unstable angina pectoris

               -  Myocardial infarction within the past 12 months

               -  Significant arrhythmias

          -  No psychiatric disorder precluding understanding of information on trial related
             topics, giving informed consent, and answering questionnaires

          -  No active uncontrolled infection

          -  No serious underlying medical condition that, in the opinion of the investigator,
             could impair the ability of the patient to participate in the trial (e.g.,
             uncontrolled diabetes mellitus or active autoimmune disease)

          -  No preexisting peripheral neuropathy &gt; grade 1

          -  No definite contraindications for the use of corticosteroids and antihistamines as
             premedication

          -  No known hypersensitivity to trial drugs or hypersensitivity to any other component of
             the trial drugs

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy to the chest

          -  At least 30 days since prior treatment in another clinical trial

          -  No concurrent drugs contraindicated for use with the trial drugs

          -  No other concurrent anticancer treatments

          -  No other concurrent experimental drugs or investigational treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ruhstaller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Stahl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kliniken Essen-Mitte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der PMU Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Bourgogne</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique François Chénieux</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Régional de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan Cedex</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne - Hôpital Nord</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31509</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen - Mitte</name>
      <address>
        <city>Essen</city>
        <zip>D-45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>D-32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>D-71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>D-35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Solingen</name>
      <address>
        <city>Solingen</city>
        <zip>D-42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais (RSV)-CHCVs</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Italiano</name>
      <address>
        <city>Viganello</city>
        <zip>CH-6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Klinik im Park</name>
      <address>
        <city>Zurich</city>
        <zip>8038</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the gastroesophageal junction</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

